
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
The 17-month-old girl who has been brought to the emergency department today has a 10-day history of what her exasperated parents describe as episodes of "stiffening."






